« Back
Home /
BRCA1 Peptide (AAP30434)

BRCA1 Peptide (AAP30434)

Item no.	AAP30434
Manufacturer	AVIVA Systems Biology
Amount	100 ug
Category	Oncology Neuroscience Neural Lineage Markers Neuroinflammation Metabolism Cholesterol & Lipid Metabolism Neural Transcription Factors Molecular Targets for Neuroscience Targets for Rodent Neurosciences Aging & Neurological Disorders Neural Signaling Neural Epigenetics Protein Aggregation, Clearance & Misfolding Peptides & Proteins Immunohistochemistry Western Blot Peptides By Organ Breast Cancer Neurodegeneration Markers
Type	Peptides
Format	Lyophilized powder
Applications	WB, IHC
Specific against	other
ECLASS 10.1	32160409
ECLASS 11.0	32160409
UNSPSC	12352202
Similar products	BRCA1
Available
Description	This is a synthetic peptide designed for use in combination with anti-BRCA1 antibody (Catalog #: AVARP02017_P050) made by Aviva Systems Biology. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.
Gene symbol	BRCA1
Protein size	680
Molecular weight	76kDa
Product format	Lyophilized powder
Gene id	672
Reconstitution and storage	Add 100ul of sterile PBS. Final peptide concentration is 1 mg/ml in PBS. For longer periods of storage, store at -20C. Avoid repeat freeze-thaw cycles.
Partner proteins	ETS2, CREBBP, EP300, MAP3K3, MED1, BRCA1, SMAD2, SMAD3, SMAD4, UBB, ACACA, ATR, BRCA2, CCNA1, CCNB1, CCND1, CDK2, CDK4, CSNK2B, E2F1, E2F4, FANCA, HDAC1, HDAC2, JUN, JUNB, JUND, LMO4, MSH2, MSH6, MYC, NFYA, NMI, NUFIP1, POU2F1, RAD51, RAD51, RB1, RBBP4, RBBP7, RBBP8, SP1, TP53, TP53, ABL1, ACACA, AKT1, AR, ATF1, ATR, AURKA, BAP1, BARD1, BRAP, BRCA1, BRCA2, BRCC3, BRIP1, CASP3, CCNA1, CCNA2, CCNB1, CCND1, CDK1, CDK2, CDK4, CDK7, CHEK2, CLSPN, COBRA1, CREBBP, CSNK2A1, CSNK2B, CSTF1, CTBP1, DCLRE1C, DHX9, E2F1, E2F4, ELK1, EP300, ESR1, FAM175A, FANCA, FANCD2, FHL2, GFI1B, H2AFX, HDAC1, HDAC2, IFI16, JAK1, JAK2, JUN, JUNB, JUND, KPNA2, KPNA6, LMO4, MAP3K3, MDC1, MED1, MED21, MLH1, MNAT1, MYC, NBN, NFKB1, NFYA, NMI, NUFIP1, POLR2A, POLR2K, POU2F1, PPP1CA, PSAP, RAD51, RB1, RBBP4, RBBP7, RBBP8, RELA, RFC1, SMAD2, SMAD3, SMAD4, SMARCA2, SMARCA4, SMC1A, SP1, STAT1, STAT3, STAT5A, TOP2A, TP53, TP53BP1, TRRAP, TUBA4A, TUBB, TUBG1, UBB, UBE2D3, UBE2L3, USF2, VCP, XRCC1, YY1, ZNF350, ABL1, ACACA, AKT1, APLP2, AR, ASM4, ATF1, ATM, ATR, AURKA, BACH1, BARD1, BLM, BRAP, BRCA1, BRCA2, BRCC3, BRD7, BRE, BRIP1, CCNA1, CCNA2, CCNB1, CCND1, CCNE1, CCR4, CDK1, CDK16, CDK2, CDK4, CDK5, CDK8, CDS1, CHEK2, CLSPN, COBRA1, CREB1, CREBBP, CSNK2A1, CSNK2B, CSTF1, CSTF2, CTBP1, CTCFL, DEF1, DHH1, DHX9, DNAJA3, E2F4, ELK4, EP300, ESR1, ETS1, FANCA, FANCD2, FHL2, FLI1, GTF2E1, GTF2F1, GTF2H4, H2AFX, H2AFY, HDAC1, HDAC2, HIST2H2AC, HIST2H3C, HSPA8, Ifi204, JAK1, JAK2, JUN, JUNB, JUND, KIF1B, KPNA2, LMO4, MAP3K3, MAP4K4, MDC1, MED1, MED13, MED17, MED21, MED23, MED24, MLH1, MLP2, MRE11A, MRPL39, MSH2, MSH3, MSH6, MYC, NBN, NCOA2, NCOA3, NFYA, NMI, NPM1, NUFIP1, NUP120, NUP133, NUP153, NUP170, NUP188, NUP2, ORC2L, ORC3L, PEG3, POLR2A, POM34, POU2F1, PPP1CA, PPP1CB, PPP1R3A, PRKDC, RAD50, RAD51, RB1, RBBP4, RBBP7, RBBP8, RBL1, RBL2, RELA, RFC1, RPL31, SMARCA2, SMARCA4, SMARCB1, SMARCC1, SMARCC2, SMARCD2, SP1, SPT4, SPT5, STAT1, STAT5A, SUB1, TOP2A, TP53, TP53BP1, TUBG1, UBA1, UBC, UBE2D1, UBE2L3, UBE3A, UIMC1, USF2, VCP, WDR48, WNT2B, XIST, ZCCHC8, ZNF350
Description of target	BRCA1, which functions as a tumor suppressor in human breast cancer cells, is a nuclear phosphoprotein which associates with RNA polymerase II holoenzyme. Mutations in BRCA1 are predicted to be responsible for approximately 45% of inherited breast cancer and more than 80% of inherited breast and ovarian cancer. BRCA1 may function as a transcriptional regulator, due to an amino terminal DNA-binding ring finger motif, nuclear localization signals, and an acidic carboxy terminal domain. BRCA1 is also a granin-like protein that functions as a secreted growth inhibitory protein. BRCA1 may normally serve as a negative regulator of mammary epithelial cell growth. This function is compromised in breast cancer either by direct mutation or by alterations in gene expression.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

AAP30434-datasheet.pdf

Request safety datasheet

Simple Order Order Subscription

Amount: 100 ug

available

Delivery expected until 10/30/2025

Express Delivery: Save 20 days

Compare

Add to wishlist

Get an offer